UNSPSC 51112515: Mannomustine dihydrochloride

This classification denotes a nitrogen mustard compound with the molecular formula C10H22Cl2N2O4.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UOZ2JJZ3I5, chemically known as d-mannitol, 1,6-bis((2-chloroethyl)amino)-1,6-dideoxy-, dihydrochloride, but more generally known as mannomustine dihydrochloride, which bears US NIH Compound Identifier 11337. European Medicines Agency schedules mannomustine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08643MIG.

Most nations, for tariff purposes, schedule mannomustine dihydrochloride under HS 29221980. SMILES: C(CCL)NC[C@H]([C@H]([C@@H]([C@@H](CNCCCL)O)O)O)O.CL.CL.

UNSPSC 51112515 Mannomustine dihydrochloride is a Commodity code covering a specific chemotherapy agent used in pharmaceutical procurement by state health agencies. State and local governments acquire this pharmaceutical through health and human services procurement channels, typically as part of broader pharmacy benefit programs or direct pharmaceutical acquisition initiatives. The issuing bodies under this code are primarily state health departments and health and human services commissions managing pharmacy benefits for state employees, retirees, and covered populations. Recent activity reflects a shift toward direct-to-manufacturer pharmaceutical procurement models that bypass traditional pharmacy benefit managers and group purchasing organizations, with state agencies seeking to manage drug costs and supply chain efficiency through negotiated net pricing and outcomes-based contracting arrangements.

The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. This RFI seeks information from manufacturers and pharmacy service providers about their capacity to establish direct contracts with state agencies and self-insured health plans outside traditional PBM and GPO channels, with emphasis on vendors' experience with negotiated net pricing models, value-based agreements, and multi-jurisdiction government purchasing arrangements. The RFI represents preliminary market intelligence gathering before a formal RFP; no award values, set-asides, or binding timelines are specified at this stage. Recent procurement activity under this code concentrates in Texas, with limited visibility into activity in other states from the available source material.